Trial Profile
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction (CARE-AMI): a Randomized Controlled Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Anxiety disorders
- Focus Pharmacodynamics
- Acronyms CARE-AMI
- 29 May 2022 Status changed from active, no longer recruiting to completed.
- 11 Nov 2020 Planned End Date changed from 1 Jul 2021 to 1 Sep 2021.
- 11 Nov 2020 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2020.